Opportunity
Simpler Grants.gov #RFA-DA-27-015
NIH Solicitation: Center for SUD Pharmacotherapeutics Training and Preclinical Support
Buyer
National Institutes of Health
Posted
May 21, 2026
Respond By
September 30, 2026
Identifier
RFA-DA-27-015
NAICS
541715
The National Institutes of Health (NIH) is seeking to establish a Center focused on advancing substance use disorder (SUD) pharmacotherapeutics through researcher training and preclinical support. - Government Buyer: - National Institutes of Health (NIH) - Scope of Opportunity: - Establish a Center to provide formal product development training for researchers in SUD pharmacotherapeutics - Offer technical and financial support to advance promising preclinical concepts - Funding Details: - Cooperative agreement with total funding of $3,000,000 - One expected award - Eligibility: - Open to government entities, educational institutions, nonprofits, businesses, and foreign organizations - Products/Services Requested: - Establishment and operation of a research and training center (no specific products, OEMs, or part numbers requested) - Unique Requirements: - Center must deliver both training and preclinical support for SUD pharmacotherapeutics - Emphasis on advancing the most promising concepts through technical and financial resources - No OEMs or vendors are specified, as this is a grant for establishing a research and training center, not a procurement of equipment or commercial products.
Description
This notice of funding opportunity aims to establish a Center that trains researchers in formal product development for new substance use disorder pharmacotherapeutics. The Center will advance the best concepts through initial experiments via technical and financial support. Eligible applicants include government entities, educational institutions, nonprofits, businesses, and other organizations, including foreign entities. The funding instrument is a cooperative agreement with a total funding amount of $3,000,000 and one expected award. Applications are due by September 30, 2026.